文献速递临床试验与 GCP流行病学与生物统计

革兰阴性菌血流感染的快速药敏试验:FAST随机临床试验

Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

在抗菌药物耐药高发地区的7个医学中心开展开放标签随机临床试验,纳入革兰阴性杆菌血流感染住院患者,比较快速表型药敏试验联合标准化药敏与单纯标准化药敏。第30天DOOR结局在快速组更优的概率为48.8%(95%CI 45.3%-52.4%),未达优效;快速组抗生素升阶梯或降阶梯中位时间快14小时(95%CI 6-22)。

要点

  • 快速药敏试验在第30天DOOR结局上未优于标准药敏试验。
  • 快速组抗生素升阶梯或降阶梯中位时间缩短14小时(95%CI 6-22)。
  • 碳青霉烯耐药亚组中位有效治疗时间快速组9.5小时 vs 标准组28小时。

核心结论

  • 在革兰阴性杆菌血流感染患者中,快速血培养药敏试验按DOOR评估未优于标准药敏试验。
  • 结合其他疗效与安全性结局,该结果可为临床实践中快速药敏试验的使用提供参考。

研究设计与样本

  • 在希腊2个、印度1个、以色列3个、西班牙1个共7个医学中心开展。
  • 纳入革兰阴性杆菌血流感染的住院成人和儿童患者。
  • 随机分为快速表型药敏试验联合标准药敏组(n=413)与单纯标准药敏组(n=437)。
  • 随机899例,850例纳入主要结局分析,中位年龄72岁(IQR 21),女性占43%。

主要发现

  • 快速组DOOR结局更优的概率为48.8%(95%CI 45.3%-52.4%),未达优效。
  • 按随机分组人群,两组至有效抗生素治疗的中位时间无差异。
  • 按随机分组人群,快速组抗生素升阶梯或降阶梯中位时间快14小时(95%CI 6-22)。
  • 其他次要结局两组间无差异。
  • 预设的碳青霉烯耐药感染亚组中,快速组至有效治疗中位时间9.5小时,标准组28小时(差值-18小时,95%CI -42至6)。

关键数值与推荐

  • 主要结局为第30天DOOR,分3类:无不良事件存活、伴不良事件存活、死亡。
  • 优效性判定标准为95%CI下限超过50%。

临床怎么用

  • 快速药敏试验未改善第30天DOOR,不宜默认其带来整体临床获益。
  • 快速药敏试验可能加快抗生素升阶梯或降阶梯,可在抗菌药物管理团队配合下考虑使用。
  • 碳青霉烯耐药感染亚组的有效治疗时间差异置信区间宽,需谨慎解读。

局限性

  • 开放标签设计。
  • 主要结局分析纳入850例,少于随机化的899例。
  • 研究仅在高耐药流行地区的7个中心开展,外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Novel blood culture diagnostics provide rapid antimicrobial susceptibility testing (AST) results for bacteria causing bloodstream infections (BSIs) but have unclear clinical impact. OBJECTIVE: To evaluate clinical outcomes of blood culture testing using a rapid AST method compared with standard AST in patients with BSIs caused by gram-negative bacilli in regions with high prevalence of antimicrobial resistance. DESIGN, SETTING, AND PARTICIPANTS: Open-label randomized clinical trial that enrolled participants from December 2023 to May 2025 (final follow-up, June 18, 2025) at 7 medical centers in Greece (n = 2), India (n = 1), Israel (n = 3), and Spain (n = 1). Hospitalized patients (adults and children) with BSIs caused by gram-negative bacilli were eligible. Statistical analysis was conducted from August 2025 to January 2026. INTERVENTION: Patients were randomized to undergo blood culture evaluation using rapid, phenotypic AST directly from positive blood cultures plus standard susceptibility testing (n = 413) vs standard susceptibility testing alone (n = 437). Local antimicrobial stewardship teams reviewed all patients and provided treatment recommendations. MAIN OUTCOMES AND MEASURES: The primary outcome was a desirability of outcome ranking (DOOR) at day 30, with 3 categories (alive without deleterious events, alive with deleterious events, and death). The difference between rapid and standard testing was summarized as the probability that the DOOR outcomes were more desirable in the rapid testing group. Superiority was concluded if the lower limit of the 95% CI exceeded 50%. Secondary outcomes included 30-day mortality, length of hospitalization, intensive care unit admission, acquisition of hospital-acquired infections, time to effective antibiotic therapy within 3 days, and time to antibiotic escalation or deescalation within 3 days. RESULTS: Of the 899 patients randomized, 850 were included in the primary outcome analysis (median [IQR] age, 72 [21] years; 43% female). The probability that DOOR outcomes were more favorable in the rapid testing group was 48.8% (95% CI, 45.3%-52.4%). Median time to effective antibiotic therapy was not different between the groups in the as-randomized population. Median time to antibiotic escalation or deescalation was faster in the rapid testing group by 14 hours (95% CI, 6-22) in the as-randomized population. There were no differences between the groups in other secondary outcomes. In the prespecified subgroup with carbapenem-resistant infections, median time to effective therapy was 9.5 hours in the rapid testing group vs 28 hours in the standard testing group (difference, -18 hours [95% CI, -42 to 6]). CONCLUSIONS AND RELEVANCE: Among patients with gram-negative bacilli BSIs, rapid blood culture AST was not superior to standard testing by DOOR. When considered with other efficacy and safety outcomes, these findings may help inform the use of rapid susceptibility testing in clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06174649.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Banerjee R, Komarow L, Li Y, et al. Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical Trial. JAMA. 2026. PMID: 41999287. doi:10.1001/jama.2026.5487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。